CoChat

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index; none of the 30 sources its claims cite is checked for support yet.

Axonal amyloid precursor protein and its fragments undergo somatodendritic endocytosis and processing

Open access
Niederst, Emily D., Reyna, Sol M., Goldstein, Lawrence S. B. · 2015 · Molecular Biology of the Cell

Abstract

Deposition of potentially neurotoxic Aβ fragments derived from amyloid precursor protein (APP) at synapses may be a key contributor to Alzheimer's disease. However, the location(s) of proteolytic processing and subsequent secretion of APP fragments from highly compartmentalized, euploid neurons that express APP and processing enzymes at normal levels is not well understood. To probe the behavior of endogenous APP, particularly in human neurons, we developed a system using neurons differentiated from human embryonic stem cells, cultured in microfluidic devices, to enable direct biochemical measurements from axons. Using human or mouse neurons in these devices, we measured levels of Aβ, sAPPα, and sAPPβ secreted solely from axons. We found that a majority of the fragments secreted from axons were processed in the soma, and many were dependent on somatic endocytosis for axonal secretion. We also observed that APP and the β-site APP cleaving enzyme were, for the most part, not dependent on endocytosis for axonal entry. These data establish that axonal entry and secretion of APP and its proteolytic processing products traverse different pathways in the somatodendritic compartment before axonal entry.

Overview

CoChat Summary

TL;DR

In mouse and human neurons, axons secrete APP fragments, but most axonal Aβ is processed in the soma through secretase- and endocytosis-dependent pathways. Full-length APP and BACE can still enter axons via endocytosis-independent routes, indicating multiple sorting pathways.

Key findings

  • Mouse hippocampal axons secreted Aβ40 at 17.1 ± 4.9 pM per chamber versus 588 ± 364 pM in bulk culture; estimated secretion was 4.0 × 10^5 ± 6 × 10^4 Aβ40 molecules per axon and 7.3 × 10^5 ± 2 × 10^5 per soma over 24 h, with axons contributing 37 ± 4% of total neuronal Aβ40.
  • Human hESC-derived neurons secreted axonal Aβ40 at 45 ± 10 pM, Aβ42 at 10 ± 3 pM, sAPPβ at 58 ± 10 pM, and sAPPα at 210 ± 80 pM; per axon over 24 h, secretion was 1.7 × 10^6 ± 5.3 × 10^5 sAPPβ, 2.3 × 10^6 ± 6.6 × 10^5 sAPPα, 1.7 × 10^6 ± 3.0 × 10^5 Aβ40, and 2.6 × 10^5 ± 1.1 × 10^4 Aβ42 molecules.
  • Somatic secretase inhibition reduced axonal Aβ: mouse γ-secretase inhibition reduced axonal Aβ40 to 30 ± 10% of vehicle, and human Compound E treatment reduced axonal Aβ40 to 68 ± 3%; the authors estimate 70–90% of mouse and 60–70% of human axonal Aβ was processed in the soma.
  • Somatic dynasore reduced axonal Aβ40 to 61 ± 10% while axonal MCP1 was unchanged; full-length APP axonal delivery and dendrite-to-axon ratios were unchanged, and ~75% of axonal APP vesicles were positive for an endosomal marker, with 48 ± 1.6% colocalizing with BACE.

Methods

  • Human neurons were differentiated from hESC lines HUES9/HSF6 on PA6 feeders with SMAD inhibitor/noggin and BDNF/GDNF/cAMP; primary mouse hippocampal neurons were cultured from P0–P1 C57/BL6 or APP mutant pups.
  • Microfluidic chambers separated somal and axonal compartments; fluidic isolation was verified with 4-kDa FITC-dextran, and conditioned media were assayed by electrochemiluminescent immunoassay for Aβ40/42, sAPPβ, sAPPα, and MCP1.
  • Pharmacological treatments included Compound E, OM99-2, β-secretase inhibitor IV, and dynasore; analyses used immunocytochemistry, live imaging, Matlab-based colocalization, ANOVA/Tukey, ANCOVA, and Mann-Whitney tests.

Limitations

  • Stated: axonal Aβ and soluble APP measurements showed high variability, possibly from degradation or cleavage after secretion; human per-soma measurements were not possible due to neuronal aggregates and nonneuronal cells; direct axonal inhibitor treatment was not possible because media flow also inhibited the somal compartment; dynasore inhibition was incomplete after 24 h; some APP antibodies had specificity limitations.
  • Stated/evident: the work is in compartmentalized in vitro cultures, not in vivo, and species or neuron-type differences may affect how much local axonal processing occurs.
  • Evident from the text: estimates of processing location depend on inhibitor diffusion/dilution assumptions and normalization, and imaging/colocalization cannot fully exclude stabilized vesicle pools or nonspecific antibody binding.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1091/mbc.e14-06-1049

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIGURE 1: Human neuronal differentiation and microfluidic devices to fluidically isolate axons. (A) Schematic of differentiation steps. (B) Neural rosette (arrow) with neuronal projections (arrowhead) growing on PA6 feeder layers. (C) βIIItub (Tuj1) in green and nestin in red. (D) p-NFH axons in green and NeuN nuclei in red. (E) Synaptophysin in red and Tuj1 in green. (F) Tyrosine hydroxylase in red and Tuj1 in green. (G) GABA in red and p-NFH in green. Scale bars: (B–D and G) 100 μm; (E) 10 μm; (F) 20 μm. (H and I) p-NFH (in red) and Map2 (in green) immunofluorescence of human day 36 neurons in microfluidic chambers. White lines denote fluidic barriers; S, soma; A, axons. (J) Diagram of new microfluidic chamber design. Neurons are plated in the two somal chambers (yellow), and one central axonal chamber is shown in red.
FIGURE 1: Human neuronal differentiation and microfluidic devices to fluidically isolate axons. (A) Schematic of differentiation steps. (B) Neural rosette (arrow) with neuronal projections (arrowhead) growing on PA6 feeder layers. (C) βIIItub (Tuj1) in green and nestin in red. (D) p-NFH axons in green and NeuN nuclei in red. (E) Synaptophysin in red and Tuj1 in green. (F) Tyrosine hydroxylase in red and Tuj1 in green. (G) GABA in red and p-NFH in green. Scale bars: (B–D and G) 100 μm; (E) 10 μm; (F) 20 μm. (H and I) p-NFH (in red) and Map2 (in green) immunofluorescence of human day 36 neurons in microfluidic chambers. White lines denote fluidic barriers; S, soma; A, axons. (J) Diagram of new microfluidic chamber design. Neurons are plated in the two somal chambers (yellow), and one central axonal chamber is shown in red.CC BY-NC-SA · PubMed Central
FIGURE 2: Mouse and human neurons secrete APP fragments from axons. (A) Secreted Aβ40 from mouse hippocampal neurons after 24 h. (B) Number of molecules of Aβ40 secreted per axon or cell body of mouse neurons in 24 h. (C) sAPPβ, sAPPα, and Aβ40 and Aβ42 measurements from human differentiated neurons after 24 h, in compartments 30–40 d. (D) Number of molecules of sAPPβ, sAPPα, and Aβ40 and Aβ42 secreted per axon of human neurons in 24 h. Error bars are SE.
FIGURE 2: Mouse and human neurons secrete APP fragments from axons. (A) Secreted Aβ40 from mouse hippocampal neurons after 24 h. (B) Number of molecules of Aβ40 secreted per axon or cell body of mouse neurons in 24 h. (C) sAPPβ, sAPPα, and Aβ40 and Aβ42 measurements from human differentiated neurons after 24 h, in compartments 30–40 d. (D) Number of molecules of sAPPβ, sAPPα, and Aβ40 and Aβ42 secreted per axon of human neurons in 24 h. Error bars are SE.CC BY-NC-SA · PubMed Central
FIGURE 3: Inhibition of secretase activity in soma reduces axonal secretion of Aβ. (A) Aβ40 from mouse hippocampal neurons in compartments, relative to vehicle control. Samples were treated with vehicle (DMSO), β inhibitor (OM99-2), or γ inhibitor (Compound E) in the somal compartment, or γ inhibitor on soma and axon (S&A) for 24 h before collection. (B) Aβ40 from human neurons in compartments, treated with vehicle, γ inhibitor (Compound E), or β inhibitor IV for 24 h in the somal compartment, relative to control. (C) sAPPβ from human neurons in compartments, treated with vehicle, γ inhibitor (Compound E), or β inhibitor IV on the soma for 24 h, relative to control. Error bars are SE; *, p < 0.05; **, p < 0.01; ***, p < 0.001.
FIGURE 3: Inhibition of secretase activity in soma reduces axonal secretion of Aβ. (A) Aβ40 from mouse hippocampal neurons in compartments, relative to vehicle control. Samples were treated with vehicle (DMSO), β inhibitor (OM99-2), or γ inhibitor (Compound E) in the somal compartment, or γ inhibitor on soma and axon (S&A) for 24 h before collection. (B) Aβ40 from human neurons in compartments, treated with vehicle, γ inhibitor (Compound E), or β inhibitor IV for 24 h in the somal compartment, relative to control. (C) sAPPβ from human neurons in compartments, treated with vehicle, γ inhibitor (Compound E), or β inhibitor IV on the soma for 24 h, relative to control. Error bars are SE; *, p < 0.05; **, p < 0.01; ***, p < 0.001.CC BY-NC-SA · PubMed Central
FIGURE 4: Inhibition of somatic endocytosis reduces axonally secreted Aβ. (A) Neuronal transcytosis. Yellow vesicles are proposed to travel by a direct, secretory pathway, while the green vesicles travel via an indirect, endosomal transcytosis pathway. (B) Somal compartments treated with vehicle (DMSO) or dynasore. Mouse Aβ40 from hippocampal neurons normalized to nuclei or axon number, relative to vehicle control. (C) Mouse MCP1 from same samples as in B, normalized to nuclei or axon number, relative to control. Error bars are SE; *, p < 0.05; ***, p < 0.001.
FIGURE 4: Inhibition of somatic endocytosis reduces axonally secreted Aβ. (A) Neuronal transcytosis. Yellow vesicles are proposed to travel by a direct, secretory pathway, while the green vesicles travel via an indirect, endosomal transcytosis pathway. (B) Somal compartments treated with vehicle (DMSO) or dynasore. Mouse Aβ40 from hippocampal neurons normalized to nuclei or axon number, relative to vehicle control. (C) Mouse MCP1 from same samples as in B, normalized to nuclei or axon number, relative to control. Error bars are SE; *, p < 0.05; ***, p < 0.001.CC BY-NC-SA · PubMed Central
FIGURE 5: APP does not require somatic endocytosis for axonal delivery. (A) Immuno­cytochemistry of mouse hippocampal neuron. Green is Map2, labeling dendrites. Red is a C-terminal APP antibody. Blue arrow denotes a Map2-negative axon. Scale bar: 50 μm. (B) Quantification of neurons labeled as in A. APP N-terminal– (A8967) and C-terminal– (Chemicon) specific antibody-labeled neurons treated with vehicle or dynasore for 24 h. Dendrite to axonal fluorescence ratio is calculated. Error bars are SE.
FIGURE 5: APP does not require somatic endocytosis for axonal delivery. (A) Immuno­cytochemistry of mouse hippocampal neuron. Green is Map2, labeling dendrites. Red is a C-terminal APP antibody. Blue arrow denotes a Map2-negative axon. Scale bar: 50 μm. (B) Quantification of neurons labeled as in A. APP N-terminal– (A8967) and C-terminal– (Chemicon) specific antibody-labeled neurons treated with vehicle or dynasore for 24 h. Dendrite to axonal fluorescence ratio is calculated. Error bars are SE.CC BY-NC-SA · PubMed Central
FIGURE 6: Axonal APP vesicles colocalize with endosome markers. Immunocytochemistry of axons with (A) Rab11 and C-terminal APP Epitomics (APPE), (B) Rab5 and N-terminal A8967 (APPN), (C) Rab7 and C-terminal APP Jonas (APPJ), and (D) BACE and N-terminal APP 5a3/1g7 (APP5). Arrows indicate single-labeled APP vesicles. Arrowheads indicate double-labeled vesicles. Respective merged images are also shown. Scale bar: 5 μm. (E and F) Histogram plots of colocalization of two representative antibody pairs. Frequency of single-labeled puncta versus double-labeled puncta is plotted as a function of distribution along axon lengths.
FIGURE 6: Axonal APP vesicles colocalize with endosome markers. Immunocytochemistry of axons with (A) Rab11 and C-terminal APP Epitomics (APPE), (B) Rab5 and N-terminal A8967 (APPN), (C) Rab7 and C-terminal APP Jonas (APPJ), and (D) BACE and N-terminal APP 5a3/1g7 (APP5). Arrows indicate single-labeled APP vesicles. Arrowheads indicate double-labeled vesicles. Respective merged images are also shown. Scale bar: 5 μm. (E and F) Histogram plots of colocalization of two representative antibody pairs. Frequency of single-labeled puncta versus double-labeled puncta is plotted as a function of distribution along axon lengths.CC BY-NC-SA · PubMed Central
FIGURE 7: Axonal APP vesicle profiles are largely unchanged after endocytic inhibition. (A–G) Veh = DMSO; Dyn = dynasore. (A) Anti-APP antibody surface labeling intensity per cell, normalized to Whole Cell Blue labeling, in differentiated human neurons. Cells treated with DMSO or dynasore 18 h. (B) APP vesicle density per micrometer in human neurons after 18 h of endocytic inhibition. APPE = C-terminal Epitomics; APPJ = C-terminal Jonas; APP5 = N-terminal APP 5a3/1g7; APPN = N-terminal APP Sigma-Aldrich 8967. (C) Endosomal and BACE vesicle density. (D) Percentage of APP vesicles that colocalize with endosomal markers or BACE. (E) Percentage of endosome or BACE vesicles that also contain APP. (F) APP vesicle-staining intensity. (G) Endosomal marker or BACE intensity on APP vesicles. Error bars are SE; *, p < 0.05; **, p < 0.01; ***, p < 0.001.
FIGURE 7: Axonal APP vesicle profiles are largely unchanged after endocytic inhibition. (A–G) Veh = DMSO; Dyn = dynasore. (A) Anti-APP antibody surface labeling intensity per cell, normalized to Whole Cell Blue labeling, in differentiated human neurons. Cells treated with DMSO or dynasore 18 h. (B) APP vesicle density per micrometer in human neurons after 18 h of endocytic inhibition. APPE = C-terminal Epitomics; APPJ = C-terminal Jonas; APP5 = N-terminal APP 5a3/1g7; APPN = N-terminal APP Sigma-Aldrich 8967. (C) Endosomal and BACE vesicle density. (D) Percentage of APP vesicles that colocalize with endosomal markers or BACE. (E) Percentage of endosome or BACE vesicles that also contain APP. (F) APP vesicle-staining intensity. (G) Endosomal marker or BACE intensity on APP vesicles. Error bars are SE; *, p < 0.05; **, p < 0.01; ***, p < 0.001.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 17 Not checked · 86 Own results and interpretations

57 more claims

Create a free account to see all 103 claims and to verify the 28 references still open.

See all claims — free account
  • It may state two separate claims as one. 29
  • Probably not a substantial claim. 17

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 61 references

Cited by

See all 64

Metadata

Authors
Niederst, E. D., Reyna, S. M., & Goldstein, L. S. B.
Affiliations
  • University of California San Diego (US)
  • Boston Children's Hospital (US)
Corresponding author
Goldstein, Lawrence S. B.
Venue
Molecular Biology of the Cell
Published
2015-01-15
Volume
26
Issue
2
Pages
205-217
ISSN
  • 1059-1524 (ISSN-L)
  • 1939-4586
OpenAlex
W2321039262
Cited by
51
References
61
Citations by year
2025: 4 · 2024: 3 · 2023: 5 · 2022: 8 · 2021: 5 · 2020: 5 · 2019: 4 · 2018: 8 · 2017: 2 · 2016: 4 · 2015: 3
FWCI
2.00
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • Molecular Biology of the Cell (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Institute on Aging (P50AG005131)
  • National Institute of General Medical Sciences (T32GM008666)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
amyloid precursor protein, axons, APP processing, amyloid-beta, sAPPα, sAPPβ, human embryonic stem cell-derived neurons, microfluidics, Alzheimer's disease, synapses
MeSH terms
Animals, Axons, Benzodiazepinones, Cell Differentiation, Cell Line, Cells, Cultured, Dendrites, Endocytosis, Humans, Hydrazones, Luminescent Proteins, Mice, Inbred C57BL, Oligopeptides, Peptide Fragments, Signal Transduction, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Mice, Knockout, Microscopy, Confocal, Microfluidic Analytical Techniques, Embryonic Stem Cells, Amyloid Precursor Protein Secretases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-19, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-19 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Axonal amyloid precursor protein and its fragments undergo somatodendritic endocytosis and processing. https://app.cochat.ai/papers/10.1091/mbc.e14-06-1049
The paper
Niederst, E. D., Reyna, S. M., & Goldstein, L. S. B. (2015). Axonal amyloid precursor protein and its fragments undergo somatodendritic endocytosis and processing. Molecular Biology of the Cell. https://doi.org/10.1091/mbc.e14-06-1049

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.